278 related articles for article (PubMed ID: 26188791)
21. Survival and prognostic factors of stage I-III breast cancer.
Laohavinij S; Ruikchuchit K; Maneechavakajorn J
J Med Assoc Thai; 2013 Mar; 96 Suppl 3():S23-34. PubMed ID: 23682519
[TBL] [Abstract][Full Text] [Related]
22. Disease-free survival according to the use of postmastectomy radiation therapy after neoadjuvant chemotherapy.
Nagar H; Boothe D; Ginter PS; Sison C; Vahdat L; Shin S; Smith M; Chao KS; Nori D; Hayes MK
Clin Breast Cancer; 2015 Apr; 15(2):128-34. PubMed ID: 25459070
[TBL] [Abstract][Full Text] [Related]
23. Survival benefit of post-mastectomy radiotherapy in breast carcinoma patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis.
Duraker N; Demir D; Bati B; Yilmaz BD; Bati Y; Çaynak ZC; Sobutay E
Jpn J Clin Oncol; 2012 Jul; 42(7):601-8. PubMed ID: 22511807
[TBL] [Abstract][Full Text] [Related]
24. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
[TBL] [Abstract][Full Text] [Related]
25. Long-term outcomes among breast cancer patients with extensive regional lymph node involvement: implications for locoregional management.
Braunstein LZ; Galland-Girodet S; Goldberg S; Warren LE; Sadek BT; Shenouda MN; Abi-Raad RF; MacDonald SM; Taghian AG
Breast Cancer Res Treat; 2015 Dec; 154(3):633-9. PubMed ID: 26585579
[TBL] [Abstract][Full Text] [Related]
26. Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors.
Hanrahan EO; Broglio KR; Buzdar AU; Theriault RL; Valero V; Cristofanilli M; Yin G; Kau SW; Hortobagyi GN; Rivera E
Cancer; 2005 Sep; 104(6):1158-71. PubMed ID: 16047352
[TBL] [Abstract][Full Text] [Related]
27. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer.
Pan K; Guan XX; Li YQ; Zhao JJ; Li JJ; Qiu HJ; Weng DS; Wang QJ; Liu Q; Huang LX; He J; Chen SP; Ke ML; Zeng YX; Xia JC
Clin Cancer Res; 2014 Jun; 20(11):3003-11. PubMed ID: 24668644
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of positron emission tomography-staged clinical N3 breast cancer treated with neoadjuvant chemotherapy, surgery, and radiotherapy.
Park HJ; Shin KH; Cho KH; Park IH; Lee KS; Ro J; Jung SY; Lee S; Kim SW; Kang HS; Chie EK; Ha SW
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e689-95. PubMed ID: 21300467
[TBL] [Abstract][Full Text] [Related]
29. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
31. Modern outcomes of inflammatory breast cancer.
Rehman S; Reddy CA; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):619-24. PubMed ID: 22445003
[TBL] [Abstract][Full Text] [Related]
32. Long-term survival outcomes following internal mammary node irradiation in stage II-III breast cancer: results of a large retrospective study with 12-year follow-up.
Chang JS; Park W; Kim YB; Lee IJ; Keum KC; Lee CG; Choi DH; Suh CO; Huh SJ
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):867-72. PubMed ID: 23747215
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors for recurrence-free survival in patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumab.
Tonyali O; Coskun U; Sener N; Inanc M; Akman T; Ulas A; Yazilitas D; Bal O; Kucukoner M; Yildirim Ozdemir N; Demirci U; Gunaydin Y; Yildiz R; Karaca H; Umit Unal O; Gumus M; Benekli M; Buyukberber S
Onkologie; 2013; 36(10):554-8. PubMed ID: 24107908
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer.
Adkins D; Brown R; Trinkaus K; Maziarz R; Luedke S; Freytes C; Needles B; Wienski D; Fracasso P; Pluard T; Moriconi W; Ryan T; Hoelzer K; Safdar S; Rearden T; Rodriguez G; Khoury H; Vij R; DiPersio J
J Clin Oncol; 1999 Jul; 17(7):2006-14. PubMed ID: 10561251
[TBL] [Abstract][Full Text] [Related]
35. Angiosarcoma of the breast.
Vorburger SA; Xing Y; Hunt KK; Lakin GE; Benjamin RS; Feig BW; Pisters PW; Ballo MT; Chen L; Trent J; Burgess M; Patel S; Pollock RE; Cormier JN
Cancer; 2005 Dec; 104(12):2682-8. PubMed ID: 16288486
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01.
Yamashiro H; Iwata H; Masuda N; Yamamoto N; Nishimura R; Ohtani S; Sato N; Takahashi M; Kamio T; Yamazaki K; Saito T; Kato M; Lee T; Kuroi K; Takano T; Yasuno S; Morita S; Ohno S; Toi M;
Breast Cancer; 2020 Jul; 27(4):631-641. PubMed ID: 32060785
[TBL] [Abstract][Full Text] [Related]
37. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
von Minckwitz G; Untch M; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Eiermann W; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Konecny GE; Denkert C; Nekljudova V; Mehta K; Loibl S
J Clin Oncol; 2012 May; 30(15):1796-804. PubMed ID: 22508812
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.
Kiess AP; McArthur HL; Mahoney K; Patil S; Morris PG; Ho A; Hudis CA; McCormick B
Cancer; 2012 Apr; 118(8):1982-8. PubMed ID: 21887681
[TBL] [Abstract][Full Text] [Related]
39. Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation.
Panoff JE; Hurley J; Takita C; Reis IM; Zhao W; Sujoy V; Gomez CR; Jorda M; Koniaris L; Wright JL
Breast Cancer Res Treat; 2011 Aug; 128(3):899-906. PubMed ID: 21475999
[TBL] [Abstract][Full Text] [Related]
40. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
Martín M; Ruiz A; Ruiz Borrego M; Barnadas A; González S; Calvo L; Margelí Vila M; Antón A; Rodríguez-Lescure A; Seguí-Palmer MA; Muñoz-Mateu M; Dorca Ribugent J; López-Vega JM; Jara C; Espinosa E; Mendiola Fernández C; Andrés R; Ribelles N; Plazaola A; Sánchez-Rovira P; Salvador Bofill J; Crespo C; Carabantes FJ; Servitja S; Chacón JI; Rodríguez CA; Hernando B; Álvarez I; Carrasco E; Lluch A
J Clin Oncol; 2013 Jul; 31(20):2593-9. PubMed ID: 23733779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]